» Articles » PMID: 15750603

The Structural Basis of Blebbistatin Inhibition and Specificity for Myosin II

Overview
Date 2005 Mar 8
PMID 15750603
Citations 163
Authors
Affiliations
Soon will be listed here.
Abstract

Molecular motors play a central role in cytoskeletal-mediated cellular processes and thus present an excellent target for cellular control by pharmacological agents. Yet very few such compounds have been found. We report here the structure of blebbistatin, which inhibits specific myosin isoforms, bound to the motor domain of Dictyostelium discoideum myosin II. This reveals the structural basis for its specificity and provides insight into the development of new agents.

Citing Articles

An allosteric inhibitor of RhoGAP class-IX myosins suppresses the metastatic features of cancer cells.

Kyriazi D, Voth L, Bader A, Ewert W, Gerlach J, Elfrink K Nat Commun. 2024; 15(1):9947.

PMID: 39550360 PMC: 11569205. DOI: 10.1038/s41467-024-54181-6.


Cytokinetic contractile ring structural progression in an early embryo: positioning of scaffolding proteins, recruitment of α-actinin, and effects of myosin II inhibition.

Henson J, Reyes G, Lo N, Herrera K, McKim Q, Herzon H Front Cell Dev Biol. 2024; 12:1483345.

PMID: 39398481 PMC: 11467475. DOI: 10.3389/fcell.2024.1483345.


Non-Muscle Myosin II A: Friend or Foe in Cancer?.

Feroz W, Park B, Siripurapu M, Ntim N, Kilroy M, Sheikh A Int J Mol Sci. 2024; 25(17).

PMID: 39273383 PMC: 11395477. DOI: 10.3390/ijms25179435.


Cell blebbing novel therapeutic possibilities to counter metastasis.

Jia W, Czabanka M, Broggini T Clin Exp Metastasis. 2024; 41(6):817-828.

PMID: 39222238 PMC: 11607095. DOI: 10.1007/s10585-024-10308-z.


Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy.

Hartman J, Hwee D, Robert-Paganin J, Chuang C, Chin E, Edell S Nat Cardiovasc Res. 2024; 3(8):1003-1016.

PMID: 39196032 PMC: 11358156. DOI: 10.1038/s44161-024-00505-0.